Guided by T cell expert, Yelena Bronevetsky, PhD, get a deeper look at how the Opto™ Cell Therapy Development workflow can be used to validate, expand, and fully characterize over a 1,000 T cells.
Polyfunctionality and cytotoxicity with recovery of live T cells from an integrated platform.
Dr. David Barrett shares insights into why children’s T cells help CAR-T cells succeed and discusses how the Opto Cell Therapy Development Workflow can provide the detailed characterization required to develop more efficacious therapies.
Review use cases for CAR-T cell screening and TCR discovery.